Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
|Articles|January 26, 2022
Pharmacy Clinical Pearl of the Day: Glioma
Author(s)Saro Arakelians, PharmD
Gliomas begin in the glial cells that surround nerve cells and help them function.
Advertisement
Clinical Pearl of the Day: Glioma
Glioma is a type of tumor that occurs in the brain and spinal cord.
Insight:
- Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function.
- Three types of glial cells can produce tumors.
- Gliomas are classified according to the type of glial cell involved in the tumor, as well as the tumor's genetic features, which can help predict how the tumor will behave over time and the treatments most likely to work.
- Types of glioma include:
- Astrocytomas, including astrocytoma, anaplastic astrocytoma, and glioblastoma.
- Ependymomas, including anaplastic ependymoma, myxopapillary ependymoma, and subependymoma.
- Oligodendrogliomas, including oligodendroglioma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.
- Symptoms may include headache, nausea, vomiting, confusion, memory loss, personality changes, difficulty with balance, and urinary incontinence.
- Diagnosis includes imaging studies, as well as neurological exams.
- Treatment includes surgery, radiation therapy, chemotherapy, targeted drug therapy, and rehab after treatments.
Sources:
Advertisement
Related to this article
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5